- 1、本文档共25页,可阅读全部内容。
- 2、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
- 3、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载。
- 4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
查看更多
课件:CVA白三稀在咳嗽中的应用解读.ppt
Slide 12: Central Role of Cysteinyl Leukotrienes in Asthma First identified in the late 1970s, the CysLTs, including LTD4, are key mediators in asthma. Early evidence of the importance of LTs in asthma was provided by their recovery in the blood, bronchoalveolar lavage fluid, and urine of patients after spontaneous or induced bronchospasm. The ability of specific LT receptor antagonists to increase airflow and reduce symptoms further supports LT involvement in this disease.1 CysLTs, including LTD4, are generated by inflammatory cells such as mast cells and eosinophils. Through multiple mechanisms, CysLTs and LT receptor occupation have been correlated with1: Increased vascular permeability and edema formation Increased mucus production with decreased mucociliary transport Recruitment of inflammatory cells, such as eosinophils, from bloodstream to airway. Eosinophil influx is a component in the inflammatory process that underlies asthma Eosinophils in the airway releasing inflammatory mediators, including cationic proteins, that can damage the epithelium. Epithelial damage can then expose sensory fibers to allow stimulation of cough or other bronchial reflexes Continued… 知道了治疗的关键是控制慢性炎症,也了解到白三烯在慢性炎症中充当着重要的角色,这就给我们选择治疗的药物体提供了依据。 治疗要达到抗炎和解痉的作用 Slide 31: Montelukast Indications and Important Imformation Montelukast is indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients 2 years and older. Montelukast should not be used as rescue medication to treat acute asthma episodes. Patients should be advised to have appropriate rescue medication available. Use of montelukast may not eliminate the need for inhaled or systemic corticosteroids. Patients should not decrease the dose or stop taking any other anti-asthma medications unless instructed by a physician. Safety and effectiveness of montelukast in patients younger than 2 years have not been established. * 白三烯受体拮抗剂 在咳嗽变异性哮喘中的应用
文档评论(0)